Cite
HARVARD Citation
Pernes, T. et al. (n.d.). S0792 The Safety of Switching From Originator Infliximab or Biosimilar CT-P13 to SB2 Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. American journal of gastroenterology. p. S405. [Online].